A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Primary Purpose
Metabolism and Nutrition Disorder, Obesity
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
NNC9204-0530
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Metabolism and Nutrition Disorder
Eligibility Criteria
Inclusion Criteria:
- Male or female, age between 18 and 55 years (both inclusive) at the time of signing informed consent
- Body mass index between 25.0 and 39.9 kg/m^2 (both inclusive) at screening.
Exclusion Criteria:
- Haemoglobin A1c (HbA1c) equal or above 6.5%
- Any clinically significant weight change (above or equal to 5% self-reported change) or dieting attempts (e.g. participation in an organized weight reduction program) within the last 90 days prior to screening
- Any prior obesity surgery or currently present gastrointestinal implant.
- Abnormal ECG (electrocardiogram) results including 2nd or 3rd degree AV-block, prolongation of the QRS complex above 120 ms, or the QTcF interval above 430 ms (males) or above 450 ms (females), or other clinically relevant abnormal results, as judged by the investigator
- A history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
- History of pancreatitis (acute or chronic)
Sites / Locations
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
NNC9204-0530
Placebo
Arm Description
Dose-escalation within the cohort before reaching final dose
Outcomes
Primary Outcome Measures
Number of treatment emergent adverse events
Secondary Outcome Measures
Area under the NNC9204-0530 serum concentration-time curve
Time to maximum serum concentration of NNC9204-0530
Change in HbA1c
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02835235
Brief Title
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Official Title
A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
July 26, 2016 (Actual)
Primary Completion Date
July 7, 2017 (Actual)
Study Completion Date
July 7, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in the United States of America. The aim of the trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects being overweight or with obesity
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolism and Nutrition Disorder, Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
NNC9204-0530
Arm Type
Experimental
Arm Description
Dose-escalation within the cohort before reaching final dose
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
NNC9204-0530
Intervention Description
Administered daily subcutaneously (s.c., under the skin)
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Administered daily subcutaneously (s.c., under the skin)
Primary Outcome Measure Information:
Title
Number of treatment emergent adverse events
Time Frame
Day 1-112
Secondary Outcome Measure Information:
Title
Area under the NNC9204-0530 serum concentration-time curve
Time Frame
Day 84-112
Title
Time to maximum serum concentration of NNC9204-0530
Time Frame
Day 84-112
Title
Change in HbA1c
Time Frame
Day -1, Day 85
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, age between 18 and 55 years (both inclusive) at the time of signing informed consent
Body mass index between 25.0 and 39.9 kg/m^2 (both inclusive) at screening.
Exclusion Criteria:
Haemoglobin A1c (HbA1c) equal or above 6.5%
Any clinically significant weight change (above or equal to 5% self-reported change) or dieting attempts (e.g. participation in an organized weight reduction program) within the last 90 days prior to screening
Any prior obesity surgery or currently present gastrointestinal implant.
Abnormal ECG (electrocardiogram) results including 2nd or 3rd degree AV-block, prolongation of the QRS complex above 120 ms, or the QTcF interval above 430 ms (males) or above 450 ms (females), or other clinically relevant abnormal results, as judged by the investigator
A history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
History of pancreatitis (acute or chronic)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85283
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68502
Country
United States
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
We'll reach out to this number within 24 hrs